aTyr Pharma, Inc.
ATYR
$0.58
$0.034.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -18.77% | -38.07% | -10.93% | 49.46% | -97.67% |
| Gross Profit | 18.77% | 38.07% | 10.93% | -48.17% | 97.67% |
| SG&A Expenses | -16.15% | 4.04% | 8.71% | 44.03% | 47.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.43% | -27.50% | -6.47% | 48.46% | 17.31% |
| Operating Income | 46.43% | 27.50% | 6.47% | -47.41% | -17.31% |
| Income Before Tax | 47.21% | 27.48% | 6.71% | -49.16% | -19.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.21% | 27.48% | 6.71% | -49.16% | -19.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | 0.00% | 0.00% | 0.00% | -- |
| Net Income | 47.22% | 27.48% | 6.71% | -49.16% | -19.78% |
| EBIT | 46.43% | 27.50% | 6.47% | -47.41% | -17.31% |
| EBITDA | 46.83% | 27.76% | 6.49% | -47.95% | -17.56% |
| EPS Basic | 51.50% | 36.03% | 21.23% | -16.38% | 3.95% |
| Normalized Basic EPS | 51.48% | 36.00% | 21.31% | -16.37% | 3.97% |
| EPS Diluted | 51.50% | 36.03% | 21.23% | -16.38% | 3.95% |
| Normalized Diluted EPS | 51.48% | 36.00% | 21.31% | -16.37% | 3.97% |
| Average Basic Shares Outstanding | 8.82% | 13.36% | 18.48% | 28.17% | 24.67% |
| Average Diluted Shares Outstanding | 8.82% | 13.36% | 18.48% | 28.17% | 24.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |